NL301276I2 - omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan - Google Patents

omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan

Info

Publication number: NL301276I2
Authority: NL; Netherlands
Prior art keywords: omaveloxolone; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2012-04-27

Application number

NL301276C

Other languages

English (en)

Original Assignee

Reata Pharmaceuticals Holdings Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-27

Filing date

2024-05-29

Publication date

2024-06-24

2024-05-29 Application filed by Reata Pharmaceuticals Holdings Llc filed Critical Reata Pharmaceuticals Holdings Llc

2024-06-24 Publication of NL301276I2 publication Critical patent/NL301276I2/nl

Links

RJCWBNBKOKFWNY-IDPLTSGASA-N n-[(4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(NC(=O)C(F)(F)C)CC[C@]21C RJCWBNBKOKFWNY-IDPLTSGASA-N 0.000 title 1
229950008128 omaveloxolone Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Toxicology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

NL301276C 2012-04-27 2024-05-29 omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan NL301276I2 (nl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261687669P	2012-04-27	2012-04-27
US201361775288P	2013-03-08	2013-03-08
US201361780444P	2013-03-13	2013-03-13
PCT/US2013/038064 WO2013163344A1 (en)	2012-04-27	2013-04-24	2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Publications (1)

Publication Number	Publication Date
NL301276I2 true NL301276I2 (nl)	2024-06-24

Family

ID=49483867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301276C NL301276I2 (nl)	2012-04-27	2024-05-29	omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan

Country Status (39)

Country	Link
US (4)	US8993640B2 (nl)
EP (2)	EP3444261B1 (nl)
JP (2)	JP6410710B2 (nl)
KR (1)	KR102101774B1 (nl)
CN (1)	CN104395332B (nl)
AR (1)	AR092823A1 (nl)
AU (1)	AU2013251602B2 (nl)
BR (1)	BR112014026640B1 (nl)
CA (1)	CA2869783C (nl)
CL (1)	CL2014002886A1 (nl)
CO (1)	CO7170182A2 (nl)
CY (2)	CY1119333T1 (nl)
DK (2)	DK3444261T3 (nl)
DO (1)	DOP2014000236A (nl)
EA (1)	EA030468B1 (nl)
ES (2)	ES2861393T3 (nl)
FI (1)	FIC20240012I1 (nl)
FR (1)	FR24C1015I1 (nl)
HK (2)	HK1207086A1 (nl)
HR (1)	HRP20171275T1 (nl)
HU (3)	HUE035673T2 (nl)
IL (1)	IL235275B (nl)
LT (2)	LT3444261T (nl)
ME (1)	ME02926B (nl)
MX (1)	MX357060B (nl)
MY (1)	MY172750A (nl)
NL (1)	NL301276I2 (nl)
NZ (1)	NZ630222A (nl)
PE (1)	PE20150160A1 (nl)
PL (2)	PL3444261T3 (nl)
PT (2)	PT2841445T (nl)
RS (2)	RS61544B1 (nl)
SG (1)	SG11201406868XA (nl)
SI (2)	SI3444261T1 (nl)
TW (2)	TWI623548B (nl)
UA (1)	UA116209C2 (nl)
UY (1)	UY34764A (nl)
WO (1)	WO2013163344A1 (nl)
ZA (1)	ZA201407326B (nl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2252283T1 (sl)	2008-01-11	2019-02-28	Reata Pharmaceuticals, Inc.	Sintetični triterpenoidi in postopki uporabe pri zdravljenju bolezni
CA2721838C (en)	2008-04-18	2017-05-23	Reata Pharmaceuticals, Inc.	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
SG190564A1 (en)	2008-04-18	2013-06-28	Reata Pharmaceuticals Inc	Compounds including an anti-inflammatory pharmacore and methods of use
EA025568B1 (ru)	2010-12-17	2017-01-30	Рита Фармасьютикалз, Инк.	Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления
US20130158077A1 (en)	2011-12-19	2013-06-20	Ares Trading S.A.	Pharmaceutical compositions
PL3444261T3 (pl)	2012-04-27	2021-07-19	Reata Pharmaceuticals, Inc.	Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, ich kompozycje farmaceutyczne i formy polimorficzne do zastosowania w leczeniu określonych stanów
US9556222B2 (en)	2012-06-15	2017-01-31	Reata Pharmaceuticals, Inc.	A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
DK2892912T3 (da)	2012-09-10	2019-06-24	Reata Pharmaceuticals Inc	C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
US9512094B2 (en)	2012-09-10	2016-12-06	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
UY35534A (es)	2013-04-24	2014-10-31	Abbvie Inc	Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
EP3212195A4 (en)	2014-10-31	2018-06-06	The Regents of The University of California	Compositions and methods for treating hiv-associated cognitive dysfunction
CA2974726C (en)	2015-02-12	2023-09-19	Reata Pharmaceuticals, Inc.	Imidazolyl tricyclic enones as antioxidant inflammation modulators
JP7074674B2 (ja)	2015-09-23	2022-05-24	リアタファーマシューティカルズインコーポレイテッド	Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
KR102486434B1 (ko)	2016-11-08	2023-01-09	리아타 파마슈티컬즈 홀딩스, 엘엘씨	바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
TWI831738B (zh)	2016-12-16	2024-02-11	美商瑞塔醫藥有限責任公司	用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
CA3101470A1 (en)	2018-05-24	2019-11-28	Renibus Therapeutics, Inc.	Methods of treating patients at risk for renal injury and renal failure
KR20210032936A (ko)	2018-06-15	2021-03-25	리아타 파마슈티컬즈, 아이엔씨.	Il-17 및 ror감마의 저해를 위한 피라졸 및 이미다졸 화합물
US12060340B2 (en)	2018-06-20	2024-08-13	Reata Pharmaceuticals, Inc	Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
CR20210087A (es)	2018-08-20	2021-05-25	Janssen Pharmaceutica Nv	Inhibidores de la interacción proteína-proteína keap1-nrf2
US20220133748A1 (en) *	2019-02-15	2022-05-05	Triterpenoid Therapeutics, Inc.	Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease
US20230077280A1 (en) *	2019-12-03	2023-03-09	Baylor College Of Medicine	Therapeutic compounds for methods of use in insulin resistance
JP2023520273A (ja)	2020-01-24	2023-05-17	トゥヴァルディセラピューティクス，インク．	治療化合物、製剤、およびその使用
EP4259155A1 (en)	2020-12-11	2023-10-18	Reata Pharmaceuticals Holdings, LLC	Synthetic triterpenoids for use in therapy
PE20231661A1 (es) *	2021-01-18	2023-10-17	Reata Pharmaceuticals Inc	Derivados de acido ursolico sinteticos y metodos de uso de los mismos
CN113197905B (zh) *	2021-04-23	2022-04-19	浙江大学	三萜类化合物在制备神经母细胞瘤治疗药物中的应用
CN113358627B (zh) *	2021-06-23	2022-07-01	华中农业大学	一种基于拉曼检测的田间快速测定茶树品质成分的方法
CN114344308A (zh) *	2021-12-22	2022-04-15	山西医科大学第二医院	甲基巴多索隆在制备防治骨关节炎的药物中的应用
WO2023244946A1 (en)	2022-06-15	2023-12-21	Tvardi Therapeutics, Inc.	Prodrugs of stat3 inhibitors
EP4349847A1 (en)	2022-09-21	2024-04-10	Sicor Società Italiana Corticosteroidi S.r.l.	Process and intermediates for preparation of omaveloxolone and salts thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5555153Y2 (nl)	1975-03-19	1980-12-20
US4395423A (en)	1978-10-10	1983-07-26	Sterling Drug Inc.	Polycyclic cyanoketones
NZ191586A (en)	1978-10-10	1981-10-19	Sterling Drug Inc	Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US5064823A (en)	1988-08-24	1991-11-12	Research Triangle Institute	Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US6025395A (en)	1994-04-15	2000-02-15	Duke University	Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
US6369101B1 (en)	1999-02-26	2002-04-09	Regents Of The University Of Minnesota	Therapeutic method to treat herpes virus infection
ATE370928T1 (de)	1999-05-14	2007-09-15	Nereus Pharmaceuticals Inc	Interleukin-1 und tumornekrosefaktor-alpha modulatoren,synthese dieser modulatoren und methoden zur anwendung dieser modulatoren
US6649654B1 (en)	1999-11-23	2003-11-18	The Regents Of The University Of California	Methods for identifying and using IKK inhibitors
JP2001240573A (ja)	2000-03-01	2001-09-04	Meiji Seika Kaisha Ltd	トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en)	2000-07-12	2002-01-17	RAJKUMAR, Sujatha	Use of dammarane-type tritepenoid saporins
US6951847B2 (en)	2000-09-29	2005-10-04	Regents Of The University Of Minnesota	Methods of treating fungal infections using lupeol
AU2001294959A1 (en)	2000-09-29	2002-04-08	Robert M. Carlson	Triterpenes having antibacterial activity
AU2001294953A1 (en)	2000-09-29	2002-04-08	Regents Of The University Of Minnesota	Triterpenes having fungicidal activity against yeast
US6878751B1 (en)	2000-10-19	2005-04-12	Imperial College Of Science Technology And Medicine	Administration of resveratrol to treat inflammatory respiratory disorders
EP1395255A4 (en)	2000-11-28	2007-09-12	Univ Texas	CDDO COMPOUNDS AND COMBINATION THERAPIES THEREOF
US7435755B2 (en)	2000-11-28	2008-10-14	The Trustees Of Dartmouth College	CDDO-compounds and combination therapies thereof
WO2002092768A2 (en)	2001-05-14	2002-11-21	University Of Maryland, Baltimore	Novel alanine transaminase enzyme and methods of use
US7176237B2 (en)	2002-01-15	2007-02-13	The Trustees Of Dartmouth College	Tricyclic-bis-enone derivatives and methods of use thereof
WO2003062260A1 (en)	2002-01-18	2003-07-31	Regents Of The University Of Minnesota	Triterpene quaternary salts as biologically active surfactants
CA2485565A1 (en)	2002-05-13	2004-08-05	Trustees Of Dartmouth College	Inhibitors and methods of use thereof
WO2004089357A2 (en)	2003-04-02	2004-10-21	Regents Of The University Of Minnesota	Anti-fungal formulation of triterpene and essential oil
WO2006029221A2 (en)	2004-09-07	2006-03-16	Pacific Arrow Limited	Anti-tumor compounds with angeloyl groups
US20050208151A1 (en)	2003-10-30	2005-09-22	Entelos, Inc.	Treatment of rheumatoid arthritis with FLIP antagonists
WO2005046732A2 (en)	2003-11-04	2005-05-26	THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH	Methods and compositions for the inhibition of hiv-1 replication
US20060258752A1 (en)	2004-02-12	2006-11-16	Vander Jagt David L	Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja)	2004-03-30	2005-11-10	Anges Mg Inc	増殖性腎疾患の予防・治療・改善剤
WO2007005879A2 (en)	2005-07-01	2007-01-11	The Johns Hopkins University	Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
JP2009530405A (ja)	2006-03-23	2009-08-27	アドバンストライフサイエンシズインコーポレイテッド	合成五環性トリテルペノイド、ならびにベツリン酸およびベツリンの誘導体
US20070249561A1 (en)	2006-04-25	2007-10-25	Taylor Bradley K	Pharmacological method for treatment of neuropathic pain
WO2008000068A1 (en)	2006-06-27	2008-01-03	Wellington Laboratories Inc.	Method for preparing 2-iodo triterpenoid compounds
JP2008110962A (ja)	2006-08-02	2008-05-15	Santen Pharmaceut Co Ltd	Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
WO2008016095A1 (fr)	2006-08-02	2008-02-07	Santen Pharmaceutical Co., Ltd.	REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
WO2008064132A2 (en)	2006-11-17	2008-05-29	Trustees Of Dartmouth College	Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US7714012B2 (en)	2006-11-17	2010-05-11	Trustees Of Dartmouth University	Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
EP2137537B8 (en)	2007-02-08	2016-06-01	Biogen MA Inc.	Compositions and Uses for Treating Multiple Sclerosis
JP2008247898A (ja)	2007-03-08	2008-10-16	Santen Pharmaceut Co Ltd	トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en)	2007-04-11	2008-10-16	John Erich Oblong	Compositions for Regulation of Hair Growth
WO2008136838A1 (en)	2007-05-04	2008-11-13	Trustees Of Dartmouth College	Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en)	2007-08-15	2012-01-03	Reata Pharmaceuticals Inc.	Forms of CDDO methyl ester
US20090048205A1 (en)	2007-08-15	2009-02-19	Colin Meyer	Combination therapy with synthetic triterpenoids and gemcitabine
WO2009058849A1 (en)	2007-10-29	2009-05-07	University Of Rochester	Use of electrophilic compounds for inducing platelet production or maintaining platelet function
SI2252283T1 (sl)	2008-01-11	2019-02-28	Reata Pharmaceuticals, Inc.	Sintetični triterpenoidi in postopki uporabe pri zdravljenju bolezni
SG190564A1 (en)	2008-04-18	2013-06-28	Reata Pharmaceuticals Inc	Compounds including an anti-inflammatory pharmacore and methods of use
CA2721838C (en)	2008-04-18	2017-05-23	Reata Pharmaceuticals, Inc.	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
WO2009146216A2 (en)	2008-04-18	2009-12-03	Reata Pharmaceuticals. Inc.	Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN102066398B (zh)	2008-04-18	2014-09-10	里亚塔医药公司	抗氧化剂炎症调节剂：c-17同系化齐墩果酸衍生物
US7915402B2 (en)	2008-04-18	2011-03-29	Reata Pharmaceuticals, Inc.	Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
JP5758801B2 (ja)	2008-07-22	2015-08-05	トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓｏｆＤａｒｔｍｏｕｔｈＣｏｌｌｅｇｅ	単環式シアノエノンおよびその使用方法説明
WO2010053817A1 (en)	2008-11-04	2010-05-14	Trustees Of Dartmouth College	Betulinic acid derivatives and methods of use thereof
CA2744388A1 (en)	2008-11-21	2010-05-27	The Johns Hopkins University	Compositions and methods for treating or preventing radiation injury
EP3254675B1 (en)	2009-02-13	2019-05-15	Reata Pharmaceuticals, Inc.	Delayed release, oral dosage compositions that contain amorphous cddo-me
EP3165606A1 (en)	2009-05-01	2017-05-10	Ophthotech Corporation	Methods for treating or preventing ophthalmological diseases
CA2795320C (en)	2010-04-12	2019-01-22	Reata Pharmaceuticals, Inc.	Method of treating obesity using antioxidant inflammation modulators
WO2011140078A1 (en)	2010-05-04	2011-11-10	Concert Pharmaceuticals, Inc.	Synthetic triterpenoid derivatives
WO2012009171A2 (en)	2010-07-15	2012-01-19	The Schepens Eye Research Institute, Inc.	Compositions and methods of treatment of corneal endothelium disorders
CN102070697A (zh)	2010-12-09	2011-05-25	中国药科大学	一种齐墩果酸衍生物、其制备方法及用途
CN102079772A (zh)	2010-12-09	2011-06-01	中国药科大学	一类五环三萜-13,28-内酯化合物、其制备方法和用途
EA025568B1 (ru)	2010-12-17	2017-01-30	Рита Фармасьютикалз, Инк.	Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления
EA022470B1 (ru)	2011-01-31	2016-01-29	Бристол-Маерс Сквибб Компани	C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
CN102153613B (zh)	2011-02-28	2013-08-14	贵州省中国科学院天然产物化学重点实验室	夏枯草酸的制备方法和应用
CN102093462B (zh)	2011-02-28	2012-11-21	贵州省中国科学院天然产物化学重点实验室	1α,2α-二羟基齐墩果酸的制备方法和应用
PL2683731T3 (pl) *	2011-03-11	2019-09-30	Reata Pharmaceuticals, Inc.	C4-monometylowe pochodne triterpenoidów i sposoby ich zastosowania
WO2012154554A1 (en)	2011-05-06	2012-11-15	Catabasis Pharmaceuticals, Inc.	Fatty acid triterpene derivatives and their uses
CN102250189B (zh)	2011-05-20	2012-08-29	中国药科大学	一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途
PL3444261T3 (pl)	2012-04-27	2021-07-19	Reata Pharmaceuticals, Inc.	Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, ich kompozycje farmaceutyczne i formy polimorficzne do zastosowania w leczeniu określonych stanów
WO2013169740A2 (en)	2012-05-08	2013-11-14	Trustees Of Dartmouth College	Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US8921419B2 (en)	2012-05-08	2014-12-30	Trustees Of Dartmouth College	Triterpenoids and compositions containing the same
US8981144B2 (en)	2012-05-08	2015-03-17	Trustees Of Dartmouth College	Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US9556222B2 (en)	2012-06-15	2017-01-31	Reata Pharmaceuticals, Inc.	A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
RU2487884C1 (ru)	2012-07-13	2013-07-20	Общество с ограниченной ответственностью "Дакор" (ООО "Дакор")	Средство, обладающее антиоксидантной, противовоспалительной, нейропротекторной, гиполипидемической, гипохолестеринемической, гипогликемической, гепатопротекторной, иммуносупрессорной активностями
CN103665087A (zh)	2012-09-03	2014-03-26	上海源力生物技术有限公司	一种萜类化合物及其在医药上的应用
WO2014040073A1 (en)	2012-09-10	2014-03-13	Reata Pharmaceuticals, Inc.	C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en)	2012-09-10	2016-12-06	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
MX2015003021A (es)	2012-09-10	2015-11-09	Abbvie Inc	Derivados de acido glicirretinico y metodos de uso de los mismos.
US20140088163A1 (en)	2012-09-10	2014-03-27	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
DK2892912T3 (da)	2012-09-10	2019-06-24	Reata Pharmaceuticals Inc	C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
US9656951B2 (en)	2012-09-28	2017-05-23	Applied Pharmaceutical Science, Inc.	Polymorphs of CDDO ethyl ester and uses thereof
CN102887936A (zh)	2012-10-24	2013-01-23	苏州晶云药物科技有限公司	2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN102875634B (zh)	2012-10-24	2014-08-20	苏州晶云药物科技有限公司	2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
UY35534A (es)	2013-04-24	2014-10-31	Abbvie Inc	Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
NZ756256A (en)	2013-08-23	2021-07-30	Reata Pharmaceuticals Inc	Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EP3097089B1 (en)	2014-01-24	2021-02-24	Reata Pharmaceuticals, Inc.	Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
CA2974726C (en)	2015-02-12	2023-09-19	Reata Pharmaceuticals, Inc.	Imidazolyl tricyclic enones as antioxidant inflammation modulators
JP7074674B2 (ja)	2015-09-23	2022-05-24	リアタファーマシューティカルズインコーポレイテッド	Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
KR102486434B1 (ko)	2016-11-08	2023-01-09	리아타 파마슈티컬즈 홀딩스, 엘엘씨	바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
TWI831738B (zh)	2016-12-16	2024-02-11	美商瑞塔醫藥有限責任公司	用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物

2013
- 2013-04-24 PL PL17175885T patent/PL3444261T3/pl unknown
- 2013-04-24 UY UY0001034764A patent/UY34764A/es active IP Right Grant
- 2013-04-24 JP JP2015509119A patent/JP6410710B2/ja active Active
- 2013-04-24 CN CN201380034275.0A patent/CN104395332B/zh active Active
- 2013-04-24 WO PCT/US2013/038064 patent/WO2013163344A1/en active Application Filing
- 2013-04-24 ES ES17175885T patent/ES2861393T3/es active Active
- 2013-04-24 EP EP17175885.7A patent/EP3444261B1/en active Active
- 2013-04-24 NZ NZ630222A patent/NZ630222A/en unknown
- 2013-04-24 HU HUE13720708A patent/HUE035673T2/en unknown
- 2013-04-24 DK DK17175885.7T patent/DK3444261T3/da active
- 2013-04-24 RS RS20210286A patent/RS61544B1/sr unknown
- 2013-04-24 PL PL13720708T patent/PL2841445T3/pl unknown
- 2013-04-24 MX MX2014013076A patent/MX357060B/es active IP Right Grant
- 2013-04-24 LT LTEP17175885.7T patent/LT3444261T/lt unknown
- 2013-04-24 KR KR1020147032968A patent/KR102101774B1/ko active IP Right Grant
- 2013-04-24 AU AU2013251602A patent/AU2013251602B2/en active Active
- 2013-04-24 RS RS20170770A patent/RS56154B1/sr unknown
- 2013-04-24 EP EP13720708.0A patent/EP2841445B1/en active Active
- 2013-04-24 SI SI201331856T patent/SI3444261T1/sl unknown
- 2013-04-24 ES ES13720708.0T patent/ES2634315T3/es active Active
- 2013-04-24 DK DK13720708.0T patent/DK2841445T3/en active
- 2013-04-24 MY MYPI2014003024A patent/MY172750A/en unknown
- 2013-04-24 BR BR112014026640-9A patent/BR112014026640B1/pt active IP Right Grant
- 2013-04-24 LT LTEP13720708.0T patent/LT2841445T/lt unknown
- 2013-04-24 CA CA2869783A patent/CA2869783C/en active Active
- 2013-04-24 PT PT137207080T patent/PT2841445T/pt unknown
- 2013-04-24 AR ARP130101383A patent/AR092823A1/es not_active Application Discontinuation
- 2013-04-24 PT PT171758857T patent/PT3444261T/pt unknown
- 2013-04-24 ME MEP-2017-178A patent/ME02926B/me unknown
- 2013-04-24 PE PE2014001894A patent/PE20150160A1/es active IP Right Grant
- 2013-04-24 EA EA201491972A patent/EA030468B1/ru unknown
- 2013-04-24 HU HUE17175885A patent/HUE053113T2/hu unknown
- 2013-04-24 SG SG11201406868XA patent/SG11201406868XA/en unknown
- 2013-04-24 US US13/869,833 patent/US8993640B2/en active Active
- 2013-04-24 TW TW106112410A patent/TWI623548B/zh active
- 2013-04-24 SI SI201330749T patent/SI2841445T1/sl unknown
- 2013-04-24 UA UAA201412683A patent/UA116209C2/uk unknown
- 2013-04-24 TW TW102114730A patent/TW201348245A/zh unknown
2014
- 2014-10-09 ZA ZA2014/07326A patent/ZA201407326B/en unknown
- 2014-10-21 DO DO2014000236A patent/DOP2014000236A/es unknown
- 2014-10-22 IL IL235275A patent/IL235275B/en active IP Right Grant
- 2014-10-24 CL CL2014002886A patent/CL2014002886A1/es unknown
- 2014-10-29 CO CO14240045A patent/CO7170182A2/es unknown
2015
- 2015-02-19 US US14/625,829 patent/US9701709B2/en active Active
- 2015-08-05 HK HK15107527.0A patent/HK1207086A1/xx unknown
- 2015-08-05 HK HK15107525.2A patent/HK1207085A1/xx unknown
2017
- 2017-06-14 US US15/622,568 patent/US11078230B2/en active Active
- 2017-08-22 HR HRP20171275TT patent/HRP20171275T1/hr unknown
- 2017-09-12 CY CY20171100959T patent/CY1119333T1/el unknown
2018
- 2018-09-25 JP JP2018178470A patent/JP6637136B2/ja active Active
2021
- 2021-03-26 CY CY20211100266T patent/CY1124130T1/el unknown
- 2021-06-25 US US17/304,778 patent/US12065464B2/en active Active
2024
- 2024-04-17 FR FR24C1015C patent/FR24C1015I1/fr active Active
- 2024-04-18 HU HUS2400010C patent/HUS2400010I1/hu unknown
- 2024-04-18 FI FIC20240012C patent/FIC20240012I1/fi unknown
- 2024-05-29 NL NL301276C patent/NL301276I2/nl unknown

Also Published As

Publication number	Publication date
EA201491972A1 (ru)	2015-02-27
TW201348245A (zh)	2013-12-01
US8993640B2 (en)	2015-03-31
ZA201407326B (en)	2016-10-26
ME02926B (me)	2018-04-20
TWI623548B (zh)	2018-05-11
EP2841445A1 (en)	2015-03-04
RS61544B1 (sr)	2021-04-29
US9701709B2 (en)	2017-07-11
HUE053113T2 (hu)	2021-06-28
MY172750A (en)	2019-12-11
ES2861393T3 (es)	2021-10-06
HRP20171275T1 (hr)	2017-10-20
PL2841445T3 (pl)	2017-10-31
NZ630222A (en)	2016-06-24
CN104395332B (zh)	2017-01-18
CA2869783A1 (en)	2013-10-31
LT3444261T (lt)	2021-05-10
SI3444261T1 (sl)	2021-04-30
US20150259377A1 (en)	2015-09-17
HUS2400010I1 (hu)	2024-05-28
AU2013251602A1 (en)	2014-10-23
UA116209C2 (uk)	2018-02-26
US12065464B2 (en)	2024-08-20
IL235275B (en)	2018-03-29
HK1207085A1 (en)	2016-01-22
MX357060B (es)	2018-06-25
CY1124130T1 (el)	2022-05-27
EP3444261A1 (en)	2019-02-20
AU2013251602B2 (en)	2017-09-28
JP2015521166A (ja)	2015-07-27
BR112014026640A2 (pt)	2017-07-18
KR102101774B1 (ko)	2020-04-20
TW201726701A (zh)	2017-08-01
US20180009839A1 (en)	2018-01-11
FR24C1015I1 (fr)	2024-06-28
RS56154B1 (sr)	2017-11-30
JP6410710B2 (ja)	2018-10-24
AR092823A1 (es)	2015-05-06
FIC20240012I1 (fi)	2024-04-18
WO2013163344A1 (en)	2013-10-31
US11078230B2 (en)	2021-08-03
PT3444261T (pt)	2021-03-12
HK1207086A1 (en)	2016-01-22
BR112014026640B1 (pt)	2021-05-18
HUE035673T2 (en)	2018-05-28
SI2841445T1 (sl)	2017-12-29
PL3444261T3 (pl)	2021-07-19
ES2634315T3 (es)	2017-09-27
CN104395332A (zh)	2015-03-04
US20210355156A1 (en)	2021-11-18
KR20150003875A (ko)	2015-01-09
JP2019011349A (ja)	2019-01-24
EA030468B1 (ru)	2018-08-31
PE20150160A1 (es)	2015-02-19
SG11201406868XA (en)	2014-11-27
PT2841445T (pt)	2017-09-01
CL2014002886A1 (es)	2015-02-06
CO7170182A2 (es)	2015-01-28
JP6637136B2 (ja)	2020-01-29
CY1119333T1 (el)	2018-02-14
LT2841445T (lt)	2017-09-11
DK3444261T3 (da)	2021-03-08
MX2014013076A (es)	2015-05-11
US20130324599A1 (en)	2013-12-05
EP3444261B1 (en)	2021-01-13
DOP2014000236A (es)	2015-04-30
EP2841445B1 (en)	2017-06-14
DK2841445T3 (en)	2017-09-11
UY34764A (es)	2013-11-29
CA2869783C (en)	2022-06-21

Publication	Publication Date	Title
NL301131I2 (nl)	2021-10-25	pemigatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301276I2 (nl)	2024-06-24	omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan
NL301119I2 (nl)	2021-09-15	Selinexor of een farmaceutisch aanvaardbaar zout ervan
NL301292I2 (nl)	2024-10-30	Iptacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301253I2 (nl)	2024-01-10	mavacamten of een farmaceutisch aanvaardbaar zout daarvan
NL301254I2 (nl)	2024-01-10	Futibatinib of een zout daarvan
NL301201I2 (nl)	2022-12-07	Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NL301191I2 (nl)	2022-12-07	voxelotor of een tautomeer of farmaceutisch aanvaardbaar zout daarvan
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
NL301248I2 (nl)	2023-11-20	atogepant of een farmaceutisch aanvaardbaar zout daarvan
FIC20230028I1 (fi)	2023-08-28	Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola
NO2022010I1 (no)	2022-04-07	ripretinib, or a pharmaceutically acceptable salt thereof
NL301234I2 (nl)	2023-07-26	maralixibat of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder maralixibatchloride
NO2022005I1 (no)	2022-02-03	Zanubrutinib or a pharmaceutically acceptable salt thereof
NL301084I2 (nl)	2021-01-28	remdesivir of een farmaceutisch aanvaardbaar zout of ester daarvan
NL301197I2 (nl)	2022-11-04	daridorexant of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder daridorexanthydrochloride
NL301245I2 (nl)	2023-11-20	Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300901I2 (nl)	2017-11-16	pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan
NL301006I2 (nl)	2020-04-14	Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301155I2 (nl)	2022-02-23	abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301291I2 (nl)	2024-10-30	sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL300963I2 (nl)	2021-03-08	inotersen of een zout daarvan
NL301128I2 (nl)	2021-10-25	Risdiplam of een farmaceutisch aanvaardbaar zout daarvan
NL301111I2 (nl)	2021-09-27	Entrectinib of een farmaceutisch aanvaardbaar zout daarvan